STOCK TITAN

Longboard Pharmaceuticals, Inc. - LBPH STOCK NEWS

Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.

Longboard Pharmaceuticals, Inc. (symbol: LBPH) is a clinical-stage biopharmaceutical company dedicated to developing novel, transformative medicines aimed at treating rare neurological diseases. With a focus on optimized pharmacology and pharmacokinetics, Longboard's proprietary pipeline features multiple potentially first- or best-in-class programs that hold broad clinical utility.

The company is currently evaluating several promising drug candidates:

  • LP352: A next-generation 5-HT2C agonist. This oral, centrally acting superagonist aims to treat developmental and epileptic encephalopathies (DEEs) while minimizing impact on 5-HT2B and 5-HT2A receptor subtypes.
  • LP143: A centrally acting, full agonist of the cannabinoid type 2 receptor (CB2). This candidate is being developed for its potential therapeutic effects in neurological conditions.
  • LP659: A highly selective, next-generation S1P receptor modulator with central action, being evaluated for its efficacy in treating neurological diseases.

Longboard Pharmaceuticals is driven by a team committed to delivering transformational medicines. The company’s focus on GPCR-targeted therapies aims to offer precise treatment options tailored to specific receptor subtypes, thereby enhancing efficacy and safety profiles. By advancing its clinical programs through rigorous scientific research and development, Longboard strives to address unmet medical needs and improve the quality of life for patients with rare neurological conditions.

Stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. as they continue to make strides in the biopharmaceutical industry.

Rhea-AI Summary

Lundbeck will acquire Longboard Pharmaceuticals in a strategic deal to enhance its neuroscience pipeline. The acquisition, valued at approximately USD 2.6 billion equity value and USD 2.5 billion net of cash, will add the innovative product bexicaserin, in late-stage development for Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin, targeting 5-HT2C receptors, has shown promising anti-seizure effects in preclinical and clinical studies. A global phase III trial, DEEp SEA, began in September 2024. Lundbeck will fund the acquisition through existing cash resources and bank financing. The deal, approved by both companies' boards, is expected to close in Q4 2024, subject to regulatory approvals. The acquisition aligns with Lundbeck's Focused Innovator strategy and aims to address unmet needs in neuro-rare conditions, potentially driving growth into the next decade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.65%
Tags
-
Rhea-AI Summary

Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on neurological diseases, has announced inducement grants for three new employees. The Compensation Committee approved non-qualified stock options to purchase 56,000 shares of common stock and 35,000 restricted stock units (RSUs) on September 30, 2024.

The stock options have an exercise price of $33.33 per share, equal to the closing price on the grant date. They will vest 25% after one year, with the remaining 75% vesting monthly over 36 months. The RSUs will vest 25% annually over four years. Both grants are subject to continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.92%
Tags
none
-
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH) has initiated its global Phase 3 DEEp SEA Study evaluating bexicaserin for treating seizures associated with Dravet syndrome in patients two years and older. The company has activated the first sites, with additional rapid-start sites expected to be activated in the coming weeks. This study is part of the broader DEEp Program, which includes two trials.

Chad Orevillo, Longboard's Executive VP and Head of Operations, highlighted the company's rapid progression from Phase 2 data to Phase 3 initiation. Mary Anne Meskis, Executive Director of Dravet Syndrome Foundation, praised Longboard's progress, noting recent Rare Pediatric Disease and Orphan Drug designations for their Dravet syndrome treatment. She emphasized the continued unmet need in Dravet syndrome and other rare epileptic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH) has received Rare Pediatric Disease designation and Orphan Drug designation from the FDA for bexicaserin (LP352) in Dravet syndrome. This follows the company's earlier Breakthrough Therapy designation for treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs). The Rare Pediatric Disease designation offers an opportunity for a Priority Review Voucher, which can be used for priority review of another Longboard compound or monetized. Longboard plans to initiate its global Phase 3 DEEp program, starting with DEEp SEA in Dravet syndrome, in the coming weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.95%
Tags
-
Rhea-AI Summary

Longboard Pharmaceuticals (LBPH) announced positive interim results from the open-label extension (OLE) of its PACIFIC Study evaluating bexicaserin in Developmental and Epileptic Encephalopathies (DEEs). Key findings include:

1. 57.7% median reduction in countable motor seizures over ~9 months
2. Sustained efficacy for both bexicaserin-treated (58.2% reduction) and placebo-to-bexicaserin groups (57.3% reduction)
3. Favorable safety and tolerability profile
4. 92.7% participant retention in the ongoing study

The company plans to initiate a global Phase 3 program later this year, with full 12-month OLE data expected in early 2024. Bexicaserin has received Breakthrough Therapy designation, highlighting its potential as a transformative treatment for DEEs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on neurological diseases, has announced inducement grants for eleven new employees. The Compensation Committee approved non-qualified stock options to purchase 203,500 shares of common stock, granted on August 31, 2024, with an exercise price of $36.08 per share. These options will vest 25% after one year and the remaining 75% in 36 monthly installments, subject to continued employment. The grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), are designed to attract and retain talent in the competitive biotech industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company developing novel medicines for neurological diseases, has announced its participation in four major investor conferences in September 2024. The company will engage in various activities including:

  • Hosting investor meetings at the Wells Fargo Healthcare Conference on September 5 in Boston
  • Presenting a fireside chat and hosting meetings at the H.C. Wainwright Global Investment Conference on September 10 in New York
  • Participating in a fireside chat and investor meetings at Baird's Global Healthcare Conference on September 11 in New York
  • Delivering a fireside chat presentation and hosting meetings at the Cantor Global Healthcare Conference on September 17 in New York

Live webcasts of available presentations will be accessible on Longboard's website and archived for at least 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
conferences
-
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH) will present data at the 15th Annual European Epilepsy Congress in Rome, Italy, from September 7-11, 2024. The company will showcase late-breaking and encore data on bexicaserin, their novel treatment for Developmental and Epileptic Encephalopathies (DEEs).

Key presentations include:

  • Interim results from the PACIFIC study open-label extension on bexicaserin's safety and tolerability
  • Efficacy and safety results from the Phase 1b/2a PACIFIC study
  • Data on bexicaserin's minimal drug interaction potential
  • Phase 1 study results showing robust brain penetration and receptor engagement
  • Preclinical data demonstrating broad antiepileptic activity

This conference participation aligns with Longboard's preparations for initiating their global Phase 3 program later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
conferences
-
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company, will host an Investor & Analyst Event on September 16, 2024, from 10 AM – noon ET at Cooley LLP, 55 Hudson Yards, New York.

The event will provide updates on the planned global Phase 3 Program evaluating bexicaserin (LP352), a novel treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for individuals aged two and older.

Key opinion leaders, including Dr. Dennis Dlugos from the Children's Hospital of Philadelphia and Ilene Penn Miller from the Rare Epilepsy Network (REN), will join Longboard's leadership team. A live Q&A session will follow the presentations.

In-person attendance is to invited research analysts and institutional investors. Virtual attendance is available to all via the webcast on Longboard's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
conferences
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company, has announced inducement grants for two new employees. The Compensation Committee approved non-qualified stock options to purchase a total of 29,000 shares of common stock. These options, granted on July 31, 2024, have an exercise price of $33.24 per share, matching the closing price on the grant date.

The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's start date and the remaining 75% vesting in 36 equal monthly installments thereafter. These grants are subject to continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employees to join Longboard.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
none

FAQ

What is the current stock price of Longboard Pharmaceuticals (LBPH)?

The current stock price of Longboard Pharmaceuticals (LBPH) is $59.68 as of November 1, 2024.

What is the market cap of Longboard Pharmaceuticals (LBPH)?

The market cap of Longboard Pharmaceuticals (LBPH) is approximately 2.3B.

What does Longboard Pharmaceuticals, Inc. specialize in?

Longboard Pharmaceuticals specializes in developing novel, transformative medicines for rare neurological diseases, focusing on optimized pharmacology and pharmacokinetics.

What are the key drug candidates in Longboard's pipeline?

Key drug candidates include LP352, a 5-HT2C agonist for DEEs, LP143, a CB2 receptor full agonist, and LP659, a selective S1P receptor modulator.

What is LP352?

LP352 is a next-generation 5-HT2C agonist in development for the potential treatment of developmental and epileptic encephalopathies (DEEs).

What is unique about LP143?

LP143 is a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), being developed for its therapeutic potential in neurological conditions.

What is the focus of Longboard Pharmaceuticals' research?

The focus is on developing centrally acting product candidates that are selective for specific G protein-coupled receptors (GPCRs) to treat neurological diseases.

Who can benefit from Longboard's medicines?

Patients with rare neurological diseases and conditions, such as developmental and epileptic encephalopathies, may benefit from Longboard's novel treatments.

How does Longboard ensure the safety of its treatments?

Longboard employs rigorous scientific research and development to ensure its treatments have optimized pharmacology and pharmacokinetics, aiming for high efficacy and safety.

Is Longboard Pharmaceuticals a publicly traded company?

Yes, Longboard Pharmaceuticals, Inc. is publicly traded under the stock symbol LBPH.

Where can I find the latest news about Longboard Pharmaceuticals?

You can stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. on their official website or trusted financial news platforms like StockTitan.

What are the potential applications of LP659?

LP659 is a next-generation, highly selective S1P receptor modulator being evaluated for its potential applications in treating neurological diseases.

Longboard Pharmaceuticals, Inc.

Nasdaq:LBPH

LBPH Rankings

LBPH Stock Data

2.33B
34.42M
1.3%
118.95%
13.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA